Cernostics, Inc., a Danville, PA-based life science company developing new molecular diagnostic tests for the fight against cancer, received $55k in funding from the Ben Franklin Technology Partners of Northeastern Pennsylvania (BFTP/NEP).
The company intends to use the funding to validate a diagnostic and prognostic test that predicts the risk of developing esophageal cancer in patients with Barrett’s Esophagus.
Mike Hoerres, CEO, Rebecca Critchley-Thorne, Ph.D., Director of Biomarker & Diagnostic Development, and Bruce B. Campbell, Director, Imaging Informatics, Cernostics will continue further development of this molecular diagnostic test with biopsy specimens and clinical data from Geisinger Health System, Danville, in order to select and refine biomarkers and complete software development. The test employs a “spatial systems biology approach” to anatomic pathological testing, in contrast with the current pathology testing that is a largely manual and subjective process.
Additional clinical validation studies will lead to commercialization of the test via Cernostics’ clinical reference laboratory.